AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19960973 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only methotrexate (MTX, 7.5 mg per week), sulfasalazine (0.5 g, tid), and meloxicam (Mobic, 7.5 mg, bid)
Number of subjects: 100
Study 17579182 — intervention group
Group type: EXPERIMENTAL
Intervention: DNAemia cut-off of 10,000 DNA copies/mL
Number of subjects: 178
Study 17579182 — intervention group
Group type: COMPARATOR
Intervention: Positive antigenemia
Number of subjects: 178
Study 17579182 — intervention group
Group type: EXPERIMENTAL
Intervention: DNAemia cut-off
Number of subjects: 178
Study 15077102 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 mg bid increased to 10 mg bid)
Number of subjects: 56
Study 15077102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 12098166 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cycles of sinewave frequencies between 1 and 35kHz delivered at 50Hz
Number of subjects: 16
Study 9414326 — intervention group
Group type: COMPARATOR
Intervention: Weekly contact with a nurse
Number of subjects: 2422
Study 9414326 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily contact with a nurse
Number of subjects: 2422
Study 9414326 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily contact with a nurse and home monitoring of uterine activity
Number of subjects: 2422
Study 7522018 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) KIU loading dose followed by an infusion of 0.5 x 10(6) KIU/h for 4 h)
Number of subjects: 60
Study 7522018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7522018 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 60
Study 29788227 — intervention group
Group type: EXPERIMENTAL
Intervention: Creating a smoke-free home (SFH)
Number of subjects: 941
Study 29788227 — intervention group
Group type: COMPARATOR
Intervention: No smoke-free home (control)
Number of subjects: 941
Study 28453721 — intervention group
Group type: EXPERIMENTAL
Intervention: lipoprotein apheresis
Number of subjects: 20
Study 28453721 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 20
Study 26320081 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intensive smoking plus alcohol intervention using cognitive behavioral therapy (CBT)
Number of subjects: 645
Study 26320081 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking intervention using CBT
Number of subjects: 645
Study 26320081 — intervention group
Group type: COMPARATOR
Intervention: Usual care (brief smoking cessation and brief alcohol counseling)
Number of subjects: 645
Study 22818224 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole 0.5mg/kg every 12 hours
Number of subjects: 37
Study 22818224 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole 1mg/kg every 12 hours
Number of subjects: 37
Study 22011457 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon consumption (2 portions per week)
Number of subjects: 0
Study 22011457 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual diet)
Number of subjects: 0
Study 19880686 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil, 150 mg
Number of subjects: 254
Study 19880686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 16540816 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused cognitive behavioral therapy (CBT; the Building Confidence Program)
Number of subjects: 40
Study 16540816 — intervention group
Group type: COMPARATOR
Intervention: Child-focused cognitive behavioral therapy (CBT) with minimal family involvement
Number of subjects: 40
Study 14533657 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (2 sprays per nostril twice daily)
Number of subjects: 78
Study 14533657 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 78
Study 14533657 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 78
Study 10674754 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-drop contusion model
Number of subjects: 27
Study 10674754 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiological recordings
Number of subjects: 27
Study 10674754 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution magnetic resonance imaging (MRI)
Number of subjects: 27
Study 10674754 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological analysis
Number of subjects: 27
Study 10674754 — intervention group
Group type: COMPARATOR
Intervention: Comparative analysis with human SCI data
Number of subjects: 27
Study 9311405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (50 mg)
Number of subjects: 30
Study 9311405 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal morphine (50 mg)
Number of subjects: 30
Study 8322146 — intervention group
Group type: EXPERIMENTAL
Intervention: Choledochoduodenostomy (CD)
Number of subjects: 130
Study 8322146 — intervention group
Group type: COMPARATOR
Intervention: Choledochojejunostomy (CJ)
Number of subjects: 130
Study 3568062 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (2 gm IV)
Number of subjects: 48
Study 3568062 — intervention group
Group type: COMPARATOR
Intervention: Control (no cefotaxime)
Number of subjects: 48
Study 30340425 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of leucine (LEU)
Number of subjects: 10
Study 30340425 — intervention group
Group type: EXPERIMENTAL
Intervention: mixed meal (protein 27.5 g, including 2.15 g of leucine) only (MEAL)
Number of subjects: 10
Study 30340425 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of leucine immediately after a mixed meal (MEAL-LEU)
Number of subjects: 10
Study 30340425 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of leucine 180 min after a mixed meal (MEAL-LEU180)
Number of subjects: 10
Study 27541690 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary LCω3PUFA intake of at least 500 mg/d
Number of subjects: 3482
Study 27541690 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly updated LCω3PUFA intake
Number of subjects: 3482
Study 27541690 — intervention group
Group type: COMPARATOR
Intervention: Not meeting the LCω3PUFA recommendation (<500 mg/d)
Number of subjects: 3482
Study 24965132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancellous screws
Number of subjects: 1000
Study 24965132 — intervention group
Group type: COMPARATOR
Intervention: Sliding hip screws
Number of subjects: 1000
Study 22339104 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal breathing (slow respiration with inspiratory pause)
Number of subjects: 20
Study 22339104 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal breathing (normal respiration)
Number of subjects: 20
Study 22339104 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal respiration)
Number of subjects: 20
Study 20361335 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of lateral node metastasis
Number of subjects: 1046
Study 20361335 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for lateral node metastasis
Number of subjects: 1046
Study 17568402 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine with ultra-low-dose naloxone
Number of subjects: 0
Study 17568402 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine alone
Number of subjects: 0
Study 15954968 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 60
Study 12027854 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia with a bupivacaine/morphine infusion (EPI-group, n=6)
Number of subjects: 14
Study 12027854 — intervention group
Group type: COMPARATOR
Intervention: Continuous i.v. infusion of morphine (MO-group, n=8)
Number of subjects: 14
Study 10624296 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with adrenaline
Number of subjects: 24
Study 10624296 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (Control)
Number of subjects: 24
Study 7795987 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous two-team approach (group 2, n = 13)
Number of subjects: 27
Study 7795987 — intervention group
Group type: COMPARATOR
Intervention: Conventional Lewis-Tanner operation (group 1, n = 14)
Number of subjects: 27
Study 1780340 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 26
Study 1780340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 7021612 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (80 mg by mouth for 3 days)
Number of subjects: 0
Study 7021612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30652171 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrinsic wheat fibre (VITACEL® wheat fibre), ∼20 grams of additional fibre per day, for 10 days
Number of subjects: 0
Study 30652171 — intervention group
Group type: COMPARATOR
Intervention: Control food products with conventional levels of fibre
Number of subjects: 0
Study 30652171 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrinsic wheat fibre (VITACEL® wheat fibre)
Number of subjects: 0
Study 30652171 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0
Study 30156578 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 1357
Study 27895044 — intervention group
Group type: EXPERIMENTAL
Intervention: GNAS c.393C>T TT genotype
Number of subjects: 1145
Study 27895044 — intervention group
Group type: EXPERIMENTAL
Intervention: GNAS c.2273C>T TT genotype
Number of subjects: 1145
Study 27895044 — intervention group
Group type: EXPERIMENTAL
Intervention: GNAS c.393C>T TT genotype (either SNP)
Number of subjects: 1145
Study 27895044 — intervention group
Group type: COMPARATOR
Intervention: GNAS c.393C>T
Number of subjects: 1145
Study 24519200 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 10 mg daily
Number of subjects: 32
Study 24519200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 22967224 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone counseling (n=462)
Number of subjects: 1386
Study 22967224 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet counseling (n=464)
Number of subjects: 1386
Study 22967224 — intervention group
Group type: COMPARATOR
Intervention: Self-help (control group)
Number of subjects: 1386
Study 22967224 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone counseling
Number of subjects: 1386
Study 22967224 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet counseling
Number of subjects: 1386
Study 20947066 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (1.5 mg/kg)
Number of subjects: 21
Study 20947066 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (.75 mg/kg)
Number of subjects: 21
Study 20947066 — intervention group
Group type: EXPERIMENTAL
Intervention: METH (20 mg)
Number of subjects: 21
Study 17535171 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Triple P - Positive Parenting Program
Number of subjects: 0
Study 17535171 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 16208088 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based diabetic education (3 months, weekly SMS recommendations)
Number of subjects: 34
Study 16208088 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study 12352293 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg/d orally twice daily) for 14 days
Number of subjects: 42
Study 12352293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 12352293 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole in GERD-positive patients
Number of subjects: 42
Study 12352293 — intervention group
Group type: COMPARATOR
Intervention: Placebo in GERD-positive patients
Number of subjects: 42
Study 12352293 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole in GERD-negative patients
Number of subjects: 42
Study 9925239 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA (25 mg twice daily)
Number of subjects: 6602
Study 9925239 — intervention group
Group type: EXPERIMENTAL
Intervention: DP (200 mg twice daily)
Number of subjects: 6602
Study 9925239 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ASA and DP
Number of subjects: 6602
Study 9925239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6602
Study 7768079 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine (30 mg) and ethanol (1 gm/kg) combination
Number of subjects: 8
Study 7768079 — intervention group
Group type: COMPARATOR
Intervention: Methamphetamine (30 mg) alone
Number of subjects: 8
Study 7768079 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (1 gm/kg) alone
Number of subjects: 8
Study 2292255 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate regression method
Number of subjects: 90
Study 2292255 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based method
Number of subjects: 90
Study 2292255 — intervention group
Group type: COMPARATOR
Intervention: Quasi-orthogonal method
Number of subjects: 90
Study 7015792 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (10 to 60 mg daily)
Number of subjects: 30
Study 7015792 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (100 to 600 mg daily)
Number of subjects: 30
Study 7015792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29337008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice-pack application for 10 minutes
Number of subjects: 69
Study 29337008 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 69
Study 25994474 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Specific Instrumentation (PSI)
Number of subjects: 80
Study 25994474 — intervention group
Group type: COMPARATOR
Intervention: Computer-Assisted Surgery (CAS)
Number of subjects: 80
Study 25618965 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric acupuncture
Number of subjects: 340
Study 25618965 — intervention group
Group type: COMPARATOR
Intervention: Control (routine therapy alone)
Number of subjects: 340
Study 23072088 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at special acupoints (Chongyang, Fenglong, Zusanli, Liangqiu)
Number of subjects: 116
Study 23072088 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at non-specific acupoints (Tiaokou, Yinshi, Futu, Dubi)
Number of subjects: 116
Study 23072088 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoints treatment
Number of subjects: 116
Study 20715733 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm group (37 degrees C)
Number of subjects: 24
Study 20715733 — intervention group
Group type: COMPARATOR
Intervention: Cold group (21 degrees C)
Number of subjects: 24
Study 17768151 — intervention group
Group type: EXPERIMENTAL
Intervention: Government legislation, restrictions on advertising, and educational programmes
Number of subjects: 0
Study 15885845 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet group (D)
Number of subjects: 77
Study 15885845 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise group (DE)
Number of subjects: 77
Study 15885845 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 77
Study 12515574 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (20mg intravenous bolus on day 0 and day 4)
Number of subjects: 340
Study 12515574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 10713317 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin dosage scheme based on a transition factor of 2.3 times the phenprocoumon dose; no specific dosage or duration mentioned.
Number of subjects: 104
Study 9126697 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 515
Study 9126697 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin plus Gentamicin
Number of subjects: 515
Study 1567347 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent psychological treatment (relaxation, thermal biofeedback, and cognitive therapy)
Number of subjects: 40
Study 1567347 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo control (pseudo-meditation and EEG alpha suppression biofeedback)
Number of subjects: 40
Study 1567347 — intervention group
Group type: COMPARATOR
Intervention: Symptom-monitoring control
Number of subjects: 40
Study 2416566 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirmenol, 200 mg twice daily
Number of subjects: 16
Study 2416566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31775313 — intervention group
Group type: EXPERIMENTAL
Intervention: MapReduce-based parallel genetic algorithm (MR-based PGA) for selecting age-related CpG-sites
Number of subjects: 16
Study 31775313 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient Boosting Regressor (GBR) model built on selected CpG-sites from the train set
Number of subjects: 16
Study 31775313 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallelized execution of the algorithm
Number of subjects: 16
Study 29633507 — intervention group
Group type: EXPERIMENTAL
Intervention: GV1001 0.4 mg, 2‐week interval
Number of subjects: 161
Study 29633507 — intervention group
Group type: EXPERIMENTAL
Intervention: GV1001 0.56 mg, 2‐week interval
Number of subjects: 161
Study 29633507 — intervention group
Group type: EXPERIMENTAL
Intervention: GV1001 0.56 mg, 4‐week interval
Number of subjects: 161
Study 29633507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 27062417 — intervention group
Group type: EXPERIMENTAL
Intervention: mCIMT combined with auditory feedback
Number of subjects: 20
Study 27062417 — intervention group
Group type: COMPARATOR
Intervention: mCIMT
Number of subjects: 20
Study 24316088 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (Nicorette Freshmint 2mg, polacrilex chewing gum)
Number of subjects: 16
Study 23328419 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified stent
Number of subjects: 380
Study 23328419 — intervention group
Group type: COMPARATOR
Intervention: Conventional stent
Number of subjects: 380
Study 23328419 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stents
Number of subjects: 380
Study 21409315 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein (Cas-meal)
Number of subjects: 12
Study 21409315 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey (Whe-meal)
Number of subjects: 12
Study 21409315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod (Cod-meal)
Number of subjects: 12
Study 21409315 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten (Glu-meal)
Number of subjects: 12
Study 21409315 — intervention group
Group type: EXPERIMENTAL
Intervention: All protein sources
Number of subjects: 12
Study 18191383 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 18191383 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 0
Study 18191383 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study 18191383 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 0
Study 18191383 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone
Number of subjects: 0
Study 18191383 — intervention group
Group type: COMPARATOR
Intervention: Risperidone vs Quetiapine
Number of subjects: 0
Study 18191383 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment groups
Number of subjects: 0
Study 18191383 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom reduction and global improvement
Number of subjects: 0
Study 16417827 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Simply White Night (consumer-available)
Number of subjects: 80
Study 16417827 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Night Effects (consumer-available)
Number of subjects: 80
Study 16417827 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence (dentist-prescribed, home-applied)
Number of subjects: 80
Study 16417827 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 12889397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression pump at 40 mmHg pressure, 10 second deflation time, 15 second inflation time
Number of subjects: 27
Study 12889397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression pump at 30 mmHg pressure
Number of subjects: 27
Study 12889397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression pump at 35 second deflation time
Number of subjects: 27
Study 12889397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression pump at 5 second inflation time
Number of subjects: 27
Study 12889397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression pump at 45 second inflation time
Number of subjects: 27
Study 12889397 — intervention group
Group type: COMPARATOR
Intervention: Control group (elevating both lower limbs)
Number of subjects: 27
Study 12889397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression pump at 70 mmHg pressure
Number of subjects: 27
Study 12889397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression pump at 60 mmHg pressure
Number of subjects: 27
Study 10228867 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU plus bolus infusion of CDDP (A‐1, B‐1)
Number of subjects: 73
Study 10228867 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU plus continuous infusion of low‐dose CDDP (A‐2, B‐2)
Number of subjects: 73
Study 8910155 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine, 10 micrograms/kg/min
Number of subjects: 30
Study 8910155 — intervention group
Group type: COMPARATOR
Intervention: Enoximone, 20 micrograms/kg/min
Number of subjects: 30
Study 1887821 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated estrogen daily plus variable-resistance weight training
Number of subjects: 20
Study 1887821 — intervention group
Group type: COMPARATOR
Intervention: 0.625 mg conjugated estrogen daily
Number of subjects: 20
Study 6089632 — intervention group
Group type: EXPERIMENTAL
Intervention: BCVPP (carmustine, cyclophosphamide, vinblastine, procarbazine, and prednisone)
Number of subjects: 293
Study 6089632 — intervention group
Group type: COMPARATOR
Intervention: MOPP (mechlorethamine hydrochloride, vincristine, procarbazine, and prednisone)
Number of subjects: 293
Study 6089632 — intervention group
Group type: EXPERIMENTAL
Intervention: BCVPP
Number of subjects: 293